Segal / Yager / Sullivan Foundations of Biochemical Psychiatry

1. Auflage 2013
ISBN: 978-1-4831-9266-6
Verlag: Elsevier Science & Techn.
Format: PDF
Kopierschutz: 1 - PDF Watermark

E-Book, Englisch, 358 Seiten, Web PDF

Foundations of Biochemical Psychiatry provides information pertinent to the development of biochemical psychiatry, including biochemical studies of psychiatric patients before and after pharmacological intervention and genetic studies. This book discusses the development of biochemical psychiatry as a significant experimental and conceptual approach to understanding mental illness. Organized into 24 chapters, this book begins with an overview of the neurochemical processes involved in the elaboration of a behavior and the extent to which alterations in those processes are responsible for behavioral differences. This text then discusses the clinical characteristics of schizophrenia, including common symptoms, natural history, and subtypes. Other chapters consider the contribution of genetic factors to the etiology of schizophrenia. This book discusses as well the similarities among hallucinations, dreams, and primary process thinking. The final chapter deals with the factors that may influence the neuroendocrine system. This book is a valuable resource for psychiatrists, neuropharmacologists, neurobiologists, behavioral biologists, and psychoanalysts.

Autoren/Hrsg.

Segal, David S.

Yager, Joel

Sullivan, John L

Inhaltsverzeichnis

1;Front Cover;1
2;Foundations of Biochemical Psychiatry;4
3;Copyright Page;5
4;Table of Contents;9
5;Preface;7
6;Reading Selections and Contributors;11
7;Acknowledgments;13
8;Chapter
1. Introduction to Fundamental Concepts;14
8.1;Abnormal Behavior;15
8.2;Biochemical Considerations;16
8.3;Research Strategies;18
9;Chapter 2. Schizophrenia;22
9.1;Clinical Description;22
9.2;Treatment;25
9.3;Reading Selections;25
10;Chapter 3. The Genetics of Schizophrenic and Schizoid Disease;31
10.1;The Basic Evidence;31
10.2;The Schizoid;33
10.3;Quantitative Aspects;36
10.4;Genetic Hypothesis;37
10.5;Modifying Factors;39
10.6;Conclusion;41
10.7;Summary;41
10.8;References and Notes;42
11;Chapter 4. Biochemical and Sleep Studies of Schizophrenia: A Review of the Literature 1960–1970: Part I. Biochemical Studies;44
11.1;The Pink Spot in Schizophrenia;53
11.2;Mauve Factor;61
11.3;Bufotenine;61
11.4;Histamine;68
11.5;Taraxein;73
11.6;Serum Factors;75
11.7;Frohman Factor;76
11.8;Serum Enzymes;78
11.9;Summary (Part 1);80
12;Chapter 5. A Review of the Literature—–1960–1970: Part II. Sleep Studies;81
12.1;Summary (Part 2);86
12.2;Conclusion;86
12.3;References;88
13;Chapter 6.
Amphetamine Psychosis: A Multi-dimensional Process;100
13.1;Predisposing Personality;103
13.2;Drug Effect;105
13.3;Behavioral Antecedents of Amphetamine Psychosis;106
13.4;Comparison with Other Organic Psychoses;109
13.5;Discussion;111
13.6;Summary and Conclusions;113
13.7;References;114
14;Chapter 7.
Drugs, Neurotransmitters, and Schizophrenia;116
14.1;Phenothiazines;117
14.2;Stimulants;118
14.3;Psychedelic Drugs;120
14.4;Phenothiazines and Acetylcholine Receptors;124
14.5;Amphetamines and Catecholamines;127
14.6;Amine-Related Enzymes in Schizophrenics;129
14.7;Amine-Methylating Enzymes that Synthesize Psychotomimetic Drugs;130
14.8;Concluding Remarks;134
14.9;References and Notes;134
15;Chapter 8.
Possible Etiology of Schizophrenia: Progressive Damage to the Noradrenergic Reward System by 6-Hydroxydopamine;138
15.1;References and Notes;146
16;Chapter 9. Affective Disorders;149
16.1;Classification;149
16.2;Treatment;152
16.3;Reading Selections;153
17;Chapter 10. Toward a Biology of Affective Disorders : Genetic Contributions;159
17.1;Evidence for a Genetic Factor;159
17.2;Heritability;162
17.3;Role of Environment;165
17.4;Phenomenology, Nosology, and Genetics;166
17.5;Mode of Genetic Transmission;170
17.6;Research Design in a Heritable Psychiatric Disorder;173
17.7;Summary and Conclusion;175
17.8;References;175
18;Chapter 11.
The Catecholamine Hypothesis of Affective Disorders: A Review of Supporting Evidence;180
18.1;Biology of Brain Monoamines;180
18.2;Studies with Antidepressive Agents;182
18.3;Studies with Reserpine and Reserpine-like Drugs;185
18.4;Studies in Patients with Affective Disorders;186
18.5;Conclusion;188
18.6;Summary;190
18.7;References;190
19;Chapter 12.
L-DOPA, Catecholamines, and Behavior: A Clinical and Biochemical Study in Depressed Patients;194
19.1;Introduction;195
19.2;Methods;197
19.3;Clinical Results;199
19.4;Biological Results;209
19.5;Discussion;210
19.6;References;216
20;Chapter 13.
Catecholamines and Affective Disorders Revised: A Critical Assessment;219
20.1;Blood and Urine;220
20.2;Blood;220
20.3;Urine;222
20.4;Cerebrospinal Fluid (CSF);224
20.5;Urine and CSF;227
20.6;Comments;229
20.7;References;230
21;Chapter 14.
Indoleamines and Affective Disorders;235
21.1;C.S.F. Studies;235
21.2;Urinary Studies;239
21.3;Summary;241
21.4;References;242
22;Chapter 15. A Cholinergic-Adrenergic Hypothesis of Mania and Depression;243
22.1;Introduction;243
22.2;Animal Behavioural Studies Demonstrating Adrenergic-Cholinergic Balance;244
22.3;Reserpine;245
22.4;Tricyclic Antidepressants;245
22.5;Atropine and Scopolamine;246
22.6;Levodopa and the Extrapyramidal System;246
22.7;Cholinomimetic Drugs;246
22.8;Adrenergic-Cholinergic Balance and Schizophrenia;247
22.9;References;248
23;Chapter 16. Neurosis;250
23.1;Classification;250
23.2;Treatment;251
23.3;Reading Selections;252
24;Chapter 17. The Evidence for Genetic Components in the Neuroses: A Review;254
24.1;Studies;254
24.2;Neurosis and Intelligence;257
24.3;Twins Studies;258
24.4;Biochemical Aspects of Anxiety Neurosis;261
24.5;Marriage and Fertility in Neurotics;263
24.6;A Genetic-Environmental Interaction Model of Neurosis;264
24.7;References;265
25;Chapter 18. Modern Biochemical Concepts of Anxiety : Implications for Psychopharmacological Treatment;267
25.1;Corticosteroids and Anxiety in Man;268
25.2;Corticosteroids and Animal Behaviour;269
25.3;Neurochemical Control of Corticosteroid Secretion;271
25.4;Neurochemistry of Known Antianxiety Drugs;274
25.5;References;278
25.6;Chapter 5. The Hyperactive Child Syndrome;281
25.7;Clinical Description;281
25.8;Treatment;282
25.9;Reading Selections;282
26;Chapter 19. How Amphetamine Acts in Minimal Brain Dysfunction;285
26.1;Behavioral Effects of Amphetamine The Neuropharmacology of Amphetamine Isomers in Animals and in Children with Minimal Brain Dysfunction;289
26.2;Conclusion;292
26.3;References;295
27;Chapter 20. Levoamphetamine and Dextroamphetamine: Comparative Efficacy in the Hyperkinetic Syndrome : Assessment by Target Symptoms;296
27.1;Method and Design;297
27.2;Results;300
27.3;Comment and Conclusions;303
27.4;References;306
28;Chapter 21. Alcoholism;307
28.1;Clinical Description;307
28.2;Treatment;309
28.3;Reading Selection;310
28.4;Chapter 22. Alcohol Problems in Adoptees Raised Apart from Alcoholic Biological Parents;311
28.5;Method;312
28.6;Results;313
28.7;Comment;317
28.8;References;320
29;Chapter 23. Psychoendocrinology;322
29.1;Neuroendocrine Function;322
29.2;Clinical Research;323
29.3;Reading Selection;324
29.4;Chapter 24. Hormonal Changes in Stress and Mental Illness;325
29.5;Endocrine Function in Depressive Illness;329
29.6;Schizophrenia;334
30;References;337
31;Glossary;343
32;Index;352